Altox

Database / Pharmaceutical impurity

Pharmaceutical impurity

1,2-Diphenyl-4-[2-(phenylsulfanyl)-ethyl]pyrazolidine-3,5-dione

1,2-Diphenyl-4-[2-(phenylsulfanyl)-ethyl]pyrazolidine-3,5-dione is listed in the pharmaceutical impurity collection under CAS 3736-92-3. Its represented structure has formula C23H20N2O2S and a calculated molecular weight of 388.49 g/mol.

2D chemical structure

O S O N N

Chemical identity

Catalog name
1,2-Diphenyl-4-[2-(phenylsulfanyl)-ethyl]pyrazolidine-3,5-dione
Common name
Not available
Chemical name
1,2-diphenyl-4-(2-phenylsulfanylethyl)pyrazolidine-3,5-dione
CAS
3736-92-3
SMILES
O=C1C(CCSc2ccccc2)C(=O)N(c2ccccc2)N1c1ccccc1
InChI
InChI=1S/C23H20N2O2S/c26-22-21(16-17-28-20-14-8-3-9-15-20)23(27)25(19-12-6-2-7-13-19)24(22)18-10-4-1-5-11-18/h1-15,21H,16-17H2
InChIKey
PLGXGMUJUXKCDD-UHFFFAOYSA-N
Associated API
Sulfinpyrazone

Record ID: Aac5d316d1982

Computed properties

C23H20N2O2S Molecular formula
388.492 g/molMolecular weight
388.1245 DaMonoisotopic exact mass
40.62 ŲTopological polar surface area
4.78 Calculated LogP (Wildman–Crippen)
113.129 cm³/molMolar refractivity (Wildman–Crippen)
3 countHydrogen-bond acceptors
0 countHydrogen-bond donors

Descriptors are calculated from the displayed SMILES. Calculated LogP is not a measured partition coefficient or a pH-specific LogD.

Molecular descriptor profile

Descriptor radar

Mol. weight LogP TPSA HBA HBD Rotatable 25 50 75 100

Structural feature counts

0 2 4 6 Count H-bond acceptors H-bond donors Rotatable bonds Rings Aromatic rings Stereo centers

Element composition

C H N O S 0 5 10 15 20 Number of atoms

Radar scale: 0–100 percentile within 25,771 distinct represented structures in this release, using the midpoint rank for ties. Larger values indicate a higher descriptor rank, not greater safety or toxicity. Element counts include hydrogen and combine isotopes under each element.

Radar values and percentile reference
DescriptorValuePercentile
Molecular weight388.49266.84
Calculated LogP (Wildman–Crippen)4.7887.71
Topological polar surface area40.6222.78
Hydrogen-bond acceptors333.13
Hydrogen-bond donors011.28
Rotatable bonds (strict)669.73

Complete molecular descriptors

PropertyCalculated valueUnit / type
Molecular formulaC23H20N2O2Sdimensionless
Molecular weight388.492g/mol
Monoisotopic exact mass388.1245Da
Topological polar surface area40.62Ų
Calculated LogP (Wildman–Crippen)4.78dimensionless
Molar refractivity (Wildman–Crippen)113.129cm³/mol
Hydrogen-bond acceptors3count
Hydrogen-bond donors0count
Rotatable bonds (strict)6count
Heavy atoms28count
Heteroatoms5count
Rings4count
Aromatic rings3count
Aliphatic rings1count
Saturated rings1count
Aromatic heterocycles0count
Aliphatic heterocycles1count
Saturated heterocycles1count
Aromatic carbocycles3count
Aliphatic carbocycles0count
Fraction of sp³ carbon atoms0.1304fraction
Formal charge0e
Disconnected components1count
Isotopically specified atoms0count
Potential atom stereocenters0count
Unspecified atom stereocenters0count
Spiro atoms0count
Bridgehead atoms0count
Labute approximate surface area168.3004Ų
Valence electrons140count
Radical electrons0count
Bertz complexity890.6108index
Balaban J1.5808index

Ring categories overlap and should not be summed. No toxicity result, PDE, HBEL or acceptable intake is inferred from these descriptors.

Toxicological services and resources for 1,2-Diphenyl-4-[2-(phenylsulfanyl)-ethyl]pyrazolidine-3,5-dione

Qualification and safety assessment of 1,2-Diphenyl-4-[2-(phenylsulfanyl)-ethyl]pyrazolidine-3,5-dione

Explore toxicological qualification of 1,2-Diphenyl-4-[2-(phenylsulfanyl)-ethyl]pyrazolidine-3,5-dione and ICH M7 mutagenic impurity assessment of 1,2-Diphenyl-4-[2-(phenylsulfanyl)-ethyl]pyrazolidine-3,5-dione for evaluation of this impurity in its pharmaceutical context.

Where data gaps need to be addressed, resources include read-across assessment for 1,2-Diphenyl-4-[2-(phenylsulfanyl)-ethyl]pyrazolidine-3,5-dione and acceptable intake and limit justification for 1,2-Diphenyl-4-[2-(phenylsulfanyl)-ethyl]pyrazolidine-3,5-dione. The relevant approach depends on the available evidence, exposure and duration of use.

Related Altox services and technical resources

Other catalogue designations with the same represented structure

These are separate catalogue entries; shared structure does not establish interchangeable pharmacopoeial designations.

Identity sources and calculation method

Identifiers originate from the source catalogues and available public identity records. InChI and InChIKey on this page are generated from the displayed SMILES. RDKit validation checks the molecular representation; it does not independently verify every catalogue assignment.

Discuss an assessment for 1,2-Diphenyl-4-[2-(phenylsulfanyl)-ethyl]pyrazolidine-3,5-dione

Explore Altox services and software through the Altox Pharma-Hub.